Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment

Diabetes Research and Clinical Practice

Volumn 123, Issue , 2017, Pages 9-17

  Kanazawa, Ippei ^a   Tanaka, Ken ichiro ^a   Notsu, Masakazu ^a   Tanaka, Sayuri ^a   Kiyohara, Nobuaki ^a   Koike, Sayo ^a   Yamane, Yuko ^b   Tada, Yuko ^c   Sasaki, Motofumi ^c   Yamauchi, Mika ^a   Sugimoto, Toshitsugu ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b Yamane Hospital   (Japan)

^c Department of Internal Medicine   (Japan)

Author keywords

HbA1c; Hypoglycemia; Insulin; Type 2 diabetes mellitus; Vildagliptin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA GLUCOSIDASE INHIBITOR; C PEPTIDE; CREATININE; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; METFORMIN; PIOGLITAZONE; SULFONYLUREA; VILDAGLIPTIN; ADAMANTANE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; NITRILE; PYRROLIDINE DERIVATIVE;

ADD ON THERAPY; ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; ANALOGS AND DERIVATIVES; ANALYSIS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; TREATMENT OUTCOME;

ADAMANTANE; ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; NITRILES; PYRROLIDINES; TREATMENT OUTCOME;

EID: 85002992130     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2016.11.010     Document Type: Article

References (27)

1. [1] Almdal, T., Scharling, H., Jensen, J.S., Vestergaard, H., The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Int Med 164 (2004), 1422–1426.
2. [2] UKPDS Group. U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995; 44: 1249–58.
3. [3] McIntosh, B., Cameron, C., Singh, S.R., Yu, C., Ahuja, T., Welton, N.J., et al. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med 5 (2011), 35–48.
4. [4] ADVANCE Collaborative Group, Patel, A., MacMahon, S., Chalmers, J., Neal, B., Billot, L., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
5. [5] Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein, H.C., Miller, M.E., Byington, R.P., Goff, D.C. Jr., Bigger, J.T., Buse, J.B., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008), 2545–2559.
6. [6] Goto, A., Arah, O.A., Goto, M., Terauchi, Y., Noda, M., Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ, 347, 2013, f4533.
7. [7] Zoungas, S., Patel, A., Chalmers, J., de Galan, B.E., Li, Q., Billot, L., et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 363 (2010), 1410–1418.
8. [8] Esposito, K., Cozzolino, D., Bellastella, G., Maiorino, M.I., Chiodini, P., Ceriello, A., et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab 13 (2011), 594–603.
9. [9] Karagiannis, T., Paschos, P., Paletas, K., Matthews, D.R., Tsapas, A., Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ, 344, 2012, e1369.
10. [10] Kohro, T., Yamazaki, T., Sato, H., Harada, K., Ohe, K., Komuro, I., et al. Trends in antidiabetic prescription patterns in Japan from 2005 to 2011. Int Heart J 54 (2013), 93–97.
11. [11] Fonseca, V., Schweizer, A., Albrecht, D., Baron, M.A., Chang, I., Dejager, S., Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 50 (2007), 1148–1155.
12. [12] Kothny, W., Foley, J., Kozlovski, P., Shao, Q., Gallwitz, B., Lukashevich, V., Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes Obes Metab 15 (2013), 252–257.
13. [13] Kozlovski, P., Foley, J., Shao, Q., Lukashevich, V., Kothny, W., Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes. World J Diabetes 4 (2013), 151–156.
14. [14] Lukashevich, V., Schweizer, A., Foley, J.E., Dickinson, S., Groop, P.H., Kothny, W., Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment. Vasc Health Risk Manage 9 (2013), 21–28.
15. [15] Tura, A., Farngren, J., Schweizer, A., Foley, J.E., Pacini, G., Ahren, B., Four-point preprandial self-monitoring of blood glucose for the assessment of glycemic control and variability in patients with type 2 diabetes treated with insulin and vildagliptin. Int J Endocrinol, 484231, 2015, 2015.
16. [16] Hirose, T., Suzuki, M., Tsumiyama, I., Efficacy and safety of vildagliptin as an add-on to insulin with or without metformin in Japanese patients with type 2 diabetes mellitus: a 12-week, double-blind, randomized study. Diabetes Ther 6 (2015), 559–571.
17. [17] Ito, D., Inoue, K., Kaneko, K., Yanagisawa, M., Sumita, T., Ikegami, Y., et al. The efficacy of vildagliptin concomitant with insulin therapy in type 2 diabetic subjects. J Clin Med Res 7 (2015), 303–307.
18. [18] Ning, G., Wang, W., Li, L., Ma, J., Lv, X., Yang, M., et al. Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus. J Diabetes 8 (2016), 345–353.
19. [19] Kim, Y.G., Min, S.H., Hahn, S., Oh, T.J., Park, K.S., Cho, Y.M., Efficacy and safety of the addition of a dipeptidyl peptidase-4 inhibitor to insulin therapy in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract 116 (2016), 86–95.
20. [20] Chen, C., Yu, Q., Zhang, S., Yang, P., Wang, C.Y., Assessing the efficacy and safety of combined DPP-4 inhibitor and insulin treatment in patients with type 2 diabetes: a meta-analysis. Int J Clin Exp Pathol 8 (2015), 14141–14150.
21. [21] Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus, Seino, Y., Nanjo, K., Tajima, N., Kadowaki, T., Kashiwagi, A., et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig 1 (2010), 212–228.
22. [22] Matsuo, S., Imai, E., Horio, M., Yasuda, Y., Tomita, K., Nitta, K., et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53 (2009), 982–992.
23. [23] Ahren, B., Schweizer, A., Dejager, S., Dunning, B.E., Nilsson, P.M., Persson, M., et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 94 (2009), 1236–1243.
24. [24] Malmgren, S., Ahren, B., DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP-glucagon counterregulatory axis in mice. Diabetologia 58 (2015), 1091–1099.
25. [25] Zettl, H., Schubert-Zsilavecz, M., Steinhilber, D., Medicinal chemistry of incretin mimetics and DPP-4 inhibitors. ChemMedChem 5 (2010), 179–185.
26. [26] Sakamoto, M., Nishimura, R., Irako, T., Tsujino, D., Ando, K., Utsunomiya, K., Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). Cardiovasc Diabetol, 11, 2012, 92.
27. [27] Fujimoto, W.Y., Overview of non-insulin-dependent diabetes mellitus (NIDDM) in different population groups. Diabetic Med., 13, 1996, S7-10.